[
  {
    "ts": null,
    "headline": "AbbVie sues US health agency over Botox price controls",
    "summary": "Feb 11 (Reuters) - AbbVie sued the U. Department of Health and Human Services on Wednesday, challenging a decision by the Centers for ‌Medicare & Medicaid Services to impose price controls for Botox.",
    "url": "https://finnhub.io/api/news?id=253c7af7ec66c2ce1838b2dd4412596a88bc6178a78208640cf4df713bbe5aff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770853751,
      "headline": "AbbVie sues US health agency over Botox price controls",
      "id": 139050531,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Feb 11 (Reuters) - AbbVie sued the U. Department of Health and Human Services on Wednesday, challenging a decision by the Centers for ‌Medicare & Medicaid Services to impose price controls for Botox.",
      "url": "https://finnhub.io/api/news?id=253c7af7ec66c2ce1838b2dd4412596a88bc6178a78208640cf4df713bbe5aff"
    }
  },
  {
    "ts": null,
    "headline": "Avalo Therapeutics Eyes Q2 2026 Phase IIb LOTUS Readout for AVTX-009 in Hidradenitis Suppurativa",
    "summary": "Avalo Therapeutics (NASDAQ:AVTX) is preparing to report phase IIb data in the second quarter of 2026 from its LOTUS trial evaluating AVTX-009 in hidradenitis suppurativa (HS), CEO Garry Neil said during a fireside chat at Guggenheim’s Emerging Outlook Biotech Summit 2026. Neil described LOTUS as a",
    "url": "https://finnhub.io/api/news?id=314cf73c20e0c70ef498d907b638fc5d339df140b6c0c1302476a80ad4b82a46",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770853157,
      "headline": "Avalo Therapeutics Eyes Q2 2026 Phase IIb LOTUS Readout for AVTX-009 in Hidradenitis Suppurativa",
      "id": 139051608,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Avalo Therapeutics (NASDAQ:AVTX) is preparing to report phase IIb data in the second quarter of 2026 from its LOTUS trial evaluating AVTX-009 in hidradenitis suppurativa (HS), CEO Garry Neil said during a fireside chat at Guggenheim’s Emerging Outlook Biotech Summit 2026. Neil described LOTUS as a",
      "url": "https://finnhub.io/api/news?id=314cf73c20e0c70ef498d907b638fc5d339df140b6c0c1302476a80ad4b82a46"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Sues HHS Over Selection Of Botox For IRA Medicare Drug Negotiations",
    "summary": "-Reuters Citing Court Filing",
    "url": "https://finnhub.io/api/news?id=952899bbd4ea624ba3c3863b6b939db244dc9b3a0025d4e0cad8c4f67d3c9334",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770833420,
      "headline": "AbbVie Sues HHS Over Selection Of Botox For IRA Medicare Drug Negotiations",
      "id": 139056667,
      "image": "",
      "related": "ABBV",
      "source": "Benzinga",
      "summary": "-Reuters Citing Court Filing",
      "url": "https://finnhub.io/api/news?id=952899bbd4ea624ba3c3863b6b939db244dc9b3a0025d4e0cad8c4f67d3c9334"
    }
  },
  {
    "ts": null,
    "headline": "2 Urgent Sells And 2 No Brainer Dividend Buys",
    "summary": "It is in our best approach to sell high and buy low. Here's how to approach it systematically today with 2 SELLS and 2 BUYS. Read the full article here.",
    "url": "https://finnhub.io/api/news?id=710180ef6607cf998857b15aaa54b1cbd366e4e984f58dca1a1a55930c6f0ac2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770826010,
      "headline": "2 Urgent Sells And 2 No Brainer Dividend Buys",
      "id": 139048960,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2396885/image_2396885.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "It is in our best approach to sell high and buy low. Here's how to approach it systematically today with 2 SELLS and 2 BUYS. Read the full article here.",
      "url": "https://finnhub.io/api/news?id=710180ef6607cf998857b15aaa54b1cbd366e4e984f58dca1a1a55930c6f0ac2"
    }
  },
  {
    "ts": null,
    "headline": "P/E Ratio Insights for AbbVie",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=1f2dfedd039bb17e39cf03cd5393732cdc3108368f9052ec2f7447e26f9810bf",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770804044,
      "headline": "P/E Ratio Insights for AbbVie",
      "id": 139043009,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=2048&height=1536",
      "related": "ABBV",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=1f2dfedd039bb17e39cf03cd5393732cdc3108368f9052ec2f7447e26f9810bf"
    }
  },
  {
    "ts": null,
    "headline": "The 5 Most Interesting Analyst Questions From AbbVie’s Q4 Earnings Call",
    "summary": "AbbVie’s fourth quarter results came in above Wall Street’s revenue and profit expectations, but the market responded negatively, reflecting concerns over certain business segments and future headwinds. Management attributed the quarter’s performance to robust growth in its immunology and neuroscience franchises, especially from SKYRIZI, RINVOQ, and Vraylar. Meanwhile, ongoing declines in HUMIRA due to biosimilar competition and continued softness in the aesthetics segment tempered overall resul",
    "url": "https://finnhub.io/api/news?id=faeb02506479e9336fde98eb34b593a227684de1a60f12c6242de1cfb9b94d3d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770788106,
      "headline": "The 5 Most Interesting Analyst Questions From AbbVie’s Q4 Earnings Call",
      "id": 139042254,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie’s fourth quarter results came in above Wall Street’s revenue and profit expectations, but the market responded negatively, reflecting concerns over certain business segments and future headwinds. Management attributed the quarter’s performance to robust growth in its immunology and neuroscience franchises, especially from SKYRIZI, RINVOQ, and Vraylar. Meanwhile, ongoing declines in HUMIRA due to biosimilar competition and continued softness in the aesthetics segment tempered overall resul",
      "url": "https://finnhub.io/api/news?id=faeb02506479e9336fde98eb34b593a227684de1a60f12c6242de1cfb9b94d3d"
    }
  }
]